Globe Life stock
GLNYSEGlobe Life Inc., Financial ServicesISIN US37959E1029
79Score 79 out of 100, Strong
Price and trend
64 / 100
Price history
+22% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 0.8% above it.
Since October 2024 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 42).
The price is 13% below its 52-week high. Largest decline in 20 years: 76% (May 2007 to March 2009).
Chart figures for advanced users
- SMA 50$166.24
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$160.59
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)42
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$130.37
- The lowest closing price of the last twelve months.
- Resistance$186.02
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Globe Life Inc. belongs to the Insurance (Life) industry (United States) and, with a market value of $12.21B, is number 20 of 33 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $6B (up 3.8% year on year) and earnings of $1.16B (up 8.4%).
- For fiscal 2026, analysts expect on average revenue of $6.4B (up 6.6%) and adjusted earnings per share of $15.50 (up 6.6%).
Show more
- MEQIRI Score 79 out of 100 (Strong): rank 105 of 976 in Financial Services, median 68.
- The P/E is 10.7 (Insurance (Life) median 11.5, own median of recent years 12.4).
- Our model puts fair value at $221.07, with the price 27% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on equityReturn on equity 19.1% over the last 12 months.Profitability 78
- Share buybacksShare count down 24% since 2020.Capital allocation 92
- Reliable dividendNo dividend cut for 27 years.Capital allocation 92
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and valuation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 80 to 79.
The fundamentals are strong overall.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- calm price action
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $184.23 and expensive above $276.34 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $267.58 (excess return model) and $174.57 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $198.77, at 7.8% it would be $254.52.
Valuation metrics
Half from the excess return model, half from earnings times the industry P/E (11.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.7% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Operating margin
- Net margin
In fiscal 2025: operating 24%, net 19%. Banks and insurers have no gross margin, and their net margin is not comparable with other industries. The score leaves both out.
Debt & balance sheet
latest quarterFor banks and insurers, deposits and liabilities are the business. Debt to equity and the current ratio say little here, and the score does not rate them.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 21 Oct 2026EPS reported $4.84 (expected $4.90)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $15.50−1.5%
- Revenue
- $6.4B−0.1%
- Earnings per share
- $16.40−0.6%
- Revenue
- $6.8B−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −5.7%Earnings guidance raised from the prior level, driven by better life underwriting margins and investment income, offset by higher financing costs, with premium growth of 2.5% to 3% (life) and 14% to 16% (health).
“In health insurance, premium revenue grew 16% to $437 million and health underwriting margin was up 1% to $99 million For the year, we expect health premium revenue to grow in the range of 14% to 16%, This is due to premium rate increases on our Medicare supplement business as well as strong sales in both our United …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 23 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 9 insiders sold, $44.73M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Majors Michael ClaySale
23 Oct 2026, EVP - Chief Strategy Officer
- Shares
- 14,377
- Price
- $154.48
- Value
- $2.22M
- Hensley Robert EdwardSale
22 Sept 2026, EVP & Chief Investment Officer
- Shares
- 10,000
- Price
- $170.07
- Value
- $1.7M
- Mitchell Robert BrianSale
7 Aug 2026, EVP, General Counsel and CRO
- Shares
- 23,000
- Price
- $183.34
- Value
- $4.22M
Show 14 more
- Darden James MatthewSale
31 Jul 2026, Co-Chairman & CEO
- Shares
- 50,000
- Price
- $182.43
- Value
- $9.12M
- Kalmbach Thomas PeterSale
30 Jul 2026, EVP & CFO
- Shares
- 21,000
- Price
- $180.06
- Value
- $3.78M
- Majors Michael ClaySale
29 Jul 2026, EVP - Chief Strategy Officer
- Shares
- 37,000
- Price
- $178.64
- Value
- $6.61M
- Kalmbach Thomas PeterSale
28 Jul 2026, EVP & CFO
- Shares
- 25,650
- Price
- $178.58
- Value
- $4.58M
- Skarjune Dolores LSale
30 Jun 2026, EVP and Chief Admin. Officer
- Shares
- 1,850
- Price
- $179.18
- Value
- $331,483
- Alston CherylSale
25 Jun 2026, Board
- Shares
- 8,258
- Price
- $179.24
- Value
- $1.48M
- Zorn Rebecca ESale
18 Jun 2026, EVP & Chief Talent Officer
- Shares
- 2,000
- Price
- $170.10
- Value
- $340,193
- Skarjune Dolores LSale
12 Jun 2026, EVP and Chief Admin. Officer
- Shares
- 4,175
- Price
- $166.18
- Value
- $693,794
- Svoboda Frank MSale
12 Jun 2026, Co-Chairman & CEO
- Shares
- 10,000
- Price
- $166.68
- Value
- $1.67M
- Svoboda Frank MSale
11 Jun 2026, Co-Chairman & CEO
- Shares
- 10,000
- Price
- $164.88
- Value
- $1.65M
- Mitchell Robert BrianSale
29 May 2026, EVP, General Counsel and CRO
- Shares
- 600
- Price
- $155.56
- Value
- $93,334
- Kalmbach Thomas PeterSale
22 May 2026, EVP & CFO
- Shares
- 7,936
- Price
- $156.59
- Value
- $1.24M
- Svoboda Frank MSale
22 May 2026, Co-Chairman & CEO
- Shares
- 20,000
- Price
- $156.68
- Value
- $3.13M
- Kalmbach Thomas PeterSale
19 May 2026, EVP & CFO
- Shares
- 11,903
- Price
- $156.61
- Value
- $1.86M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Globe Life
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
976 rated companies in Financial Services
- This company
- 79
- Sector median
- 68
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Insurance (Life)
The next larger and next smaller companies by market value
- KGI Financial Holding2883.TW $18.55B71
- T&D Holdings8795.T $14.93B68
- HDFC Life InsuranceHDFCLIFE.NS $13.3B52
- Unum GroupUNM $12.61B50
- Japan Post Insurance7181.T $12.13B59
- Voya FinancialVOYA $9.26B63
- Jackson FinancialJXN $9.21B61
- PrimericaPRI $8.97B88
ETFs that hold Globe Life
Held by 32 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR S&P 500 Low Volatility UCITS ETF (Acc)SPY1 | 0.90% | 0.35% | €106.3M |
| iShares Ageing Population UCITS ETF2B77 | 0.48% | 0.40% | €807M |
| State Street SPDR S&P U.S. Dividend Aristocrats UCITS ETF (Dist)SPYD | 0.32% | 0.35% | €3.62B |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.24% | 0.30% | €944.34M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.24% | 0.43% | €2.48B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.20% | 0.39% | €188.08M |
| iShares STOXX USA Equity Multifactor UCITS ETFIBCY | 0.19% | 0.20% | €47.95M |
| Invesco S&P 500 QVM UCITS ETFQVMP | 0.19% | 0.35% | €50.82M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.